Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-15 DOI:10.2217/imt-2023-0313

Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L Santorelli, Thomas Burke, Nathan A Pennell

{"title":"Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer.","authors":"Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L Santorelli, Thomas Burke, Nathan A Pennell","doi":"10.2217/imt-2023-0313","DOIUrl":null,"url":null,"abstract":"Aim: We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab-platinum-pemetrexed (induction) in US community oncology settings. Methods: Patients initiating induction were retrospectively identified. Patients continuing pembrolizumab afterward underwent chart review. Clinical outcomes were described by maintenance pemetrexed exposure after inverse probability of treatment weighting (IPTW). Results: Median induction pembrolizumab and pemetrexed durations were 5.1 and 4.2 months. Among patients continuing pembrolizumab after induction, 64% received maintenance pemetrexed. Common discontinuation reasons for induction pemetrexed were completion of planned therapy (79%) and partial response (68%) and progressive disease (38%) and toxicity (29%) for maintenance pemetrexed. After IPTW, median overall survival and real-world progression-free survival were longer in patients continuing pembrolizumab with versus without maintenance pemetrexed (20.3 vs 12.0 months and 10.3 vs 5.8 months, respectively). Conclusion: Patient characteristics and planned treatment decisions affect maintenance pemetrexed utilization in the community oncology setting.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"453-464"},"PeriodicalIF":2.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/imt-2023-0313","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab-platinum-pemetrexed (induction) in US community oncology settings. Methods: Patients initiating induction were retrospectively identified. Patients continuing pembrolizumab afterward underwent chart review. Clinical outcomes were described by maintenance pemetrexed exposure after inverse probability of treatment weighting (IPTW). Results: Median induction pembrolizumab and pemetrexed durations were 5.1 and 4.2 months. Among patients continuing pembrolizumab after induction, 64% received maintenance pemetrexed. Common discontinuation reasons for induction pemetrexed were completion of planned therapy (79%) and partial response (68%) and progressive disease (38%) and toxicity (29%) for maintenance pemetrexed. After IPTW, median overall survival and real-world progression-free survival were longer in patients continuing pembrolizumab with versus without maintenance pemetrexed (20.3 vs 12.0 months and 10.3 vs 5.8 months, respectively). Conclusion: Patient characteristics and planned treatment decisions affect maintenance pemetrexed utilization in the community oncology setting.

查看原文本刊更多论文

转移性非小细胞肺癌患者使用彭博拉珠单抗-铂-培美曲塞诱导治疗后培美曲塞维持治疗的疗效分层。

目的：我们评估了在美国社区肿瘤学机构中开始一线使用彭博利珠单抗-铂-培美曲塞（诱导）的转移性非鳞状非小细胞肺癌（mNSCLC）患者的治疗模式和结果。研究方法回顾性识别开始诱导治疗的患者。之后继续使用彭博利珠单抗的患者接受病历审查。根据逆治疗概率加权（IPTW）后的培美曲塞维持量描述临床结果。结果彭博利珠单抗和培美曲塞的中位诱导疗程分别为5.1个月和4.2个月。在诱导后继续使用彭博利珠单抗的患者中，64%接受了培美曲塞的维持治疗。诱导培美曲塞的常见停药原因是完成计划治疗（79%）和部分应答（68%），而维持培美曲塞的常见停药原因是疾病进展（38%）和毒性（29%）。IPTW后，继续使用pembrolizumab和不使用培美曲塞维持治疗的患者的中位总生存期和实际无进展生存期更长（分别为20.3个月对12.0个月和10.3个月对5.8个月）。结论患者特征和计划治疗决策会影响社区肿瘤治疗中培美曲塞的使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.